Gossamer Bio announced up to $250 million in financing to support the program through potential FDA approval.
Public source
Publisher name
Public post
A lot has happened since our last update. Since reporting PROSERA topline results earlier this year, we’ve been focused on determining the optimal regulatory and strateg…
Company
Gossamer Bio
Vision * Connection * Innovation
- Industry
- Biotechnology Research
- Location
- San Diego, US
- Company size
- 51–200 employees
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Our goal is to enhance the lives of people living with rare diseases.
See moreLatest activity
Latest activity from Gossamer Bio
7 signals
Presence & Recognition
Gossamer Bio is presenting its upcoming presentations at ERS 2026 on the effects of seralutinib on pulmonary vascular remodeling and targeted genetic profiling of PAH-predisposing genes.
Presence & Recognition
Gossamer Bio is presenting an oral presentation on exploratory analysis of a PDGFRB protein quantitative trait locus and seralutinib treatment response in the phase 3 PROSERA PAH study.
Legal & Regulatory
Gossamer Bio reported on determining the optimal regulatory and strategic path forward for seralutinib following its PROSERA topline results.
Discover more
Similar signals
Similar public activity from other companies.
Capital & Finance
EIT Pharma, Inc.
EIT Pharma, Inc. closed an oversubscribed $35 million Series A financing led by Propel Bio Partners with participation from Good Ventures, Arrowtown, and other investors.
Capital & Finance
Korsana Biosciences
Korsana Biosciences closed a $380 million financing round to support its work in the coming years, including through multiple clinical milestones for its lead program KRSA-028.
Capital & Finance
Superluminal Medicines Inc.
Superluminal Medicines Inc. secured $60M Series B financing to advance its MC4R program into the clinic and build out its pipeline of GPCR-targeted medicines.
Capital & Finance
Moonwalk Biosciences
Moonwalk Biosciences secured a $70 million Series B funding round directed at completing IND-enabling studies for its lead adipose-targeted siRNA candidate MW101 and taking it into first-in-human studies in late 2027.
Capital & Finance
Typewriter Therapeutics, Inc.